Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 13/20 | 0.53 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29348125 | 0.96 | NLRP3 (0.53) | NLRP3AKR1B1MEN1KMT2ATP53 | |
| SCHEMBL29348115 | 0.89 | NLRP3 (0.51) | NLRP3KMT2ATP53LMNAALOX15 | |
| SCHEMBL29348102 | 0.88 | NLRP3 (0.49) | NLRP3AKR1B1TP53 | |
| SCHEMBL24077116 | 0.86 | NLRP3 (0.66) | NLRP3AKR1B1MEN1KMT2A | |
| SCHEMBL24077037 | 0.84 | NLRP3 (0.55) | NLRP3AKR1B1MEN1KMT2A | |
| SCHEMBL29348127 | 0.84 | NLRP3 (0.46) | NLRP3AKR1B1MEN1KMT2ATP53 | |
| SCHEMBL24834573 | 0.79 | NLRP3 (0.52) | NLRP3AKR1B1KMT2A | |
| SCHEMBL29348117 | 0.79 | NLRP3 (0.46) | NLRP3AKR1B1 | |
| SCHEMBL24077052 | 0.79 | NLRP3 (0.62) | NLRP3KMT2ATP53LMNAALOX15 | |
| SCHEMBL24834575 | 0.79 | NLRP3 (0.51) | NLRP3AKR1B1KMT2ATP53LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239757-A1 | PHTHALAZINONE DERIVATES AS NLRP3 INFLAMMASOME INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239757-A1 | PHTHALAZINONE DERIVATES AS NLRP3 INFLAMMASOME INHIBITORS | NLRP3, NLRP1, PYCARD | NLRP3 1/4885AKR1B1 320/4885MEN1 2642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.